Pharmaceutics (Dec 2022)

Nanoparticles Obtained from Zein for Encapsulation of Mesalazine

  • Izabela Borges C. Lima,
  • Lina Clara G. A. I. Moreno,
  • Ana Victória Peres,
  • Ana Cristina Gramoza Santana,
  • Adonias Carvalho,
  • Mariana H. Chaves,
  • Lorena Lima,
  • Rayran Walter Sousa,
  • Dalton Dittz,
  • Hercília M. L. Rolim,
  • Lívio César Cunha Nunes

DOI
https://doi.org/10.3390/pharmaceutics14122830
Journal volume & issue
Vol. 14, no. 12
p. 2830

Abstract

Read online

We encapsulated MSZ in zein nanoparticles (NP-ZN) using a desolvation method followed by drying in a mini spray dryer. These nanoparticles exhibited a size of 266.6 ± 52 nm, IPD of 0.14 ± 1.1 and zeta potential of −36.4 ± 1.5 mV, suggesting colloidal stability. Quantification using HPLC showed a drug-loaded of 43.8 µg/mg. SEM demonstrated a spherical morphology with a size variation from 220 to 400 nm. A FTIR analysis did not show drug spectra in the NPs in relation to the physical mixture, which suggests drug encapsulation without changing its chemical structure. A TGA analysis showed thermal stability up to 300 °C. In vitro release studies demonstrated gastroresistance and a sustained drug release at pH 7.4 (97.67 ± 0.32%) in 120 h. The kinetic model used for the release of MSZ from the NP-ZN in a pH 1.2 medium was the Fickian diffusion, in a pH 6.8 medium it was the Peppas–Sahlin model with the polymeric relaxation mechanism and in a pH 7.4 medium it was the Korsmeyer–Peppas model with the Fickian release mechanism, or “Case I”. An in vitro cytotoxicity study in the CT26.WT cell line showed no basal cytotoxicity up to 500 μg/mL. The NP-ZN showed to be a promising vector for the sustained release of MSZ in the colon by oral route.

Keywords